Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash from Financing Activities: 2019-2023

Historic Cash from Financing Activities for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2023 value amounting to -$1,000.

  • ADC Therapeutics' Cash from Financing Activities rose 99.89% to -$1,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $73.9 million, marking a year-over-year increase of 8335.79%. This contributed to the annual value of $97.1 million for FY2024, which is 31.38% up from last year.
  • ADC Therapeutics' Cash from Financing Activities amounted to -$1,000 in Q4 2023, which was down 100.29% from $349,000 recorded in Q3 2023.
  • In the past 5 years, ADC Therapeutics' Cash from Financing Activities ranged from a high of $267.1 million in Q4 2021 and a low of -$898,855 during Q4 2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $25,985 (2021), whereas its average is $28.4 million.
  • In the last 5 years, ADC Therapeutics' Cash from Financing Activities plummeted by 100.51% in 2022 and then soared by 29,008,830.16% in 2023.
  • Over the past 5 years, ADC Therapeutics' Cash from Financing Activities (Quarterly) stood at $100.4 million in 2019, then reached -$278,000 in 2020, then spiked by 99.89% to $267.1 million in 2021, then slumped by 100.34% to -$898,855 in 2022, then soared by 99.89% to -$1,000 in 2023.
  • Its Cash from Financing Activities was -$1,000 in Q4 2023, compared to $349,000 in Q3 2023 and $73.1 million in Q2 2023.